没有交叉反应,免疫接种还会一样吗?
该文讨论疫苗学中的交叉反应与交叉保护概念,指出国家卫生机构正收集其重要性的证据,部分疫苗的交叉保护已获临床或许可后数据支持,影响疫苗设计、开发与评估,理想抗原本应包含相关病原体间保守同源表位,新型佐剂与抗原递送平台可提升交叉反应性,评估免疫规划价值时应考虑疫苗超越疫苗型别疾病的全面影响。
要点
- 交叉反应指疫苗抗原诱导的对非疫苗靶向病原体类型的免疫应答。
- 交叉保护指对相关非疫苗微生物类型的临床保护,部分疫苗已有临床或许可后数据支持。
- 理想疫苗抗原应包含相关病原体类型间保守同源的表位。
核心结论
- 不断增长的证据有助于更好理解疫苗超越疫苗型别疾病的全面影响。
- 评估免疫规划全面价值时应考虑交叉反应与交叉保护的作用。
研究设计与样本
- 原文为疫苗学概念综述,未报告系统检索范围与样本量。
主要发现
- 国家卫生当局正在收集关于交叉反应重要性的越来越多证据。
- 部分疫苗的交叉保护已获临床研究和/或许可后数据支持。
- 将相关疫苗引入免疫规划已显示对相关非疫苗微生物所致疾病的有益影响。
- 这些知识影响了新疫苗在真实环境中的设计、开发和评估方式。
- 一些新疫苗现以具有更广泛保护范围为目标进行设计。
关键数值与推荐
- 理想疫苗抗原包括相关病原体类型间具有保守同源性的表位。
- 使用具有更强免疫刺激特性的新型佐剂可有助于改善疫苗整体交叉反应性。
- 使用抗原递送平台也可有助于改善疫苗整体交叉反应性。
临床怎么用
- 在评估疫苗接种规划全面价值时,应考虑疫苗对非疫苗型别相关病原体所致疾病的影响。
- 新疫苗设计可考虑纳入相关病原体类型间保守同源表位以拓宽保护范围。
局限性
- 原文为概念性综述,未报告具体研究样本量、效应量或统计阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
"Cross-reactivity" (the observed immune response against pathogen types not specifically targeted by the vaccine antigen composition) and "cross-protection" (clinical protection against related non-vaccine microorganism types) are vaccinology concepts that are attracting renewed interest in the context of disease prevention. National health authorities are collecting mounting evidence of the importance of cross-reactivity. For some vaccines, this has been substantiated by cross-protection data from clinical studies and/or post-licensure data, where their introduction into immunization programmes has shown beneficial impacts on disease caused by related non-vaccine microorganisms. This knowledge has influenced the way new vaccines are designed, developed, and evaluated in real-life settings. Some of the new vaccines are now designed with the specific aim of having a greater breadth of protection. Ideal vaccine antigens therefore include epitopes with conserved homology across related pathogen types, because it is not always possible to include the antigens of all the individual types of a given pathogen species. The use of novel adjuvants with greater immunostimulatory properties can also contribute to improved overall vaccine cross-reactivity, as could the use of antigen delivery platforms. The growing body of evidence allows us to better understand the full impact of vaccines - beyond vaccine-type disease - which should be taken into consideration when assessing the full value of vaccination programmes.
引用
- Vojtek I, Buchy P, Doherty TM, et al. Would immunization be the same without cross-reactivity? Vaccine. 2018. PMID: 30591255. doi:10.1016/j.vaccine.2018.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。